Mechanism

Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market

Retrieved on: 
Wednesday, May 1, 2024
Research, Infectious Diseases, Clinical Trials, Health Technology, Philanthropy, General Health, Pharmaceutical, Health, Science, Oncology, Brain, MCI, Cancer, IP, Blood, Magnetic resonance, Immunotherapy, Pharmacotherapy, Speech, Digital, Therapy, Moa, Patient, Physician, Movement, Biomarker, Immune system, Mechanism, Sensory deprivation, Medical imaging

Remepy, a pioneer in “hybrid drugs,” today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M.

Key Points: 
  • Remepy, a pioneer in “hybrid drugs,” today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M.
  • The digital molecules are designed for hybrid drug experiences.
  • Remepy’s innovative approach creates a new market for hybrid medications, and a whole new world of data and IP assets for pharmaceutical companies.
  • Remepy is pioneering Hybrid Drugs: traditional drugs combined with digital therapeutics that are personalized and enhance the effect of pharmaceutical treatments.

Cerevance Announces Presentation at AD/PD™ 2024 International Conference

Retrieved on: 
Tuesday, February 27, 2024
Shift, Therapy, Epigenomics, Central nervous system, Alzheimer's disease, KCNK10, Astrocyte, Date, Conference, Mechanism, CNS, Gene, DSM-IV codes

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.
  • Overview: The NETSseq platform produces deep transcriptomic and epigenomic profiles from post-mortem human brain tissue.
  • One of these genes, KCNK10, is specifically expressed in astrocytes and oligodendrocytes, and its role in regulating glutamate uptake has been validated.
  • Therapeutic Targets, Mechanisms for Treatment: Astroglia; Poster Shift 2: Friday, March 8 - Saturday, March 9, 2024

Non-Lesional Filaggrin Expression is Predictive of Asthma Development in Children with Atopic Dermatitis

Retrieved on: 
Wednesday, February 14, 2024
AAAAI, Research, Multimedia, TEWL, Atopic dermatitis, Parent, Skin, Risk, Mechanism, FLG, PFT, Patient, Journal, Diagnosis, Wheeze, Ageing, American Academy, Pharmaceutical industry

MILWAUKEE, Feb. 14, 2024 /PRNewswire-PRWeb/ -- Filaggrin (FLG) expression in non-lesional skin and observations of the skin barrier can lead to early diagnosis for children with asthma according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting, in Washington, DC, this month.

Key Points: 
  • Low Filaggrin expression in children aged 2 to 3 years old is a significant predictor of school-age asthma.
  • Specifically, filaggrin expression in the normal appearing skin predicts asthma development and is a better predictor than parent-report of physician-diagnosed asthma" says primary author Wan Chi Chang, MS.
  • In the study, pulmonary function testing (PFT) was conducted in 96 children, aged 7 to 8 years old, with atopic dermatitis from the Mechanisms of Progression from Atopic Dermatitis to Asthma in Children cohort.
  • Logistic regression evaluated the predictability of physician-diagnosed asthma reported by parents, transepidermal water loss (TEWL), SCORing Atopic Dermatitis (SCORAD) and skin expression of FLG for asthma.

OncoHost's PROphet® Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung Cancer

Retrieved on: 
Tuesday, October 3, 2023
Probability, IgG4-related ophthalmic disease, Therapy, Progression-free survival, Cancer, Data collection, Biomarker, Inflammation, Carboplatin, Immunotherapy, Inflammatory bowel disease, Etoposide, Protein, Mechanism, MD, Patient, Machine learning, Medicine, Mall of America, Caregiver, Safety, Disease, Pharmaceutical industry, OS

BINYAMINA, Israel , Oct. 3, 2023 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a collaboration with Hengenix Biotech, Inc. (Henlius USA), affiliated with Shanghai Henlius Biotech, Inc., a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Henlius USA will utilize OncoHost's PROphet® platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive Phase III clinical trial (NCT05468489). The trial is evaluating the efficacy and safety of Serplulimab plus chemotherapy (carboplatin - etoposide) in previously untreated US-based patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Key Points: 
  • Henlius USA will utilize OncoHost's PROphet® platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive Phase III clinical trial ( NCT05468489 ).
  • The trial is evaluating the efficacy and safety of Serplulimab plus chemotherapy (carboplatin - etoposide) in previously untreated US-based patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
  • "Our shared goal is to improve cancer patients' outcomes by developing robust, scientifically sound technologies to support them and their caregivers.
  • We believe that such collaborations hold the potential to bring new hope to those affected by this challenging disease."

Global Knowledge Management Strategic Business Report 2023: Market to Reach $2.1 Trillion by 2030 - Growing Need for Data Analysis in Various Industries Drives Significance of KM - ResearchAndMarkets.com

Retrieved on: 
Friday, September 29, 2023
Professional Services, Data Analytics, Knowledge, Real, Nuclear knowledge management, Process, System, Compound annual growth rate, Mechanism, Knowledge management, Pandemic, Growth, New Normal, Drohobych Mechanical Technological College, SME, Speciality chemicals, Tourism

The "Knowledge Management - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Knowledge Management - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Knowledge Management estimated at US$558.4 Billion in the year 2022, is projected to reach a revised size of US$2.1 Trillion by 2030, growing at a CAGR of 18.3% over the analysis period 2022-2030.
  • The global market encompassing Systems, Mechanisms & Technologies, Processes, Infrastructure, Large Enterprises, Small and Medium-sized Enterprises (SMEs), and Knowledge Management exhibits promising growth prospects.
  • Revenue figures are anticipated to experience consistent growth from 2022 to 2030, building upon a stable expansion observed between 2017 and 2022.

Global Knowledge Management Markets Report, 2022-2023 & 2030: Myriad Benefits of Knowledge Management Tools to Fuel Market Growth

Retrieved on: 
Friday, September 22, 2023
Knowledge, Real, Nuclear knowledge management, Process, System, Compound annual growth rate, Mechanism, Knowledge management, Pandemic, Growth, New Normal, Drohobych Mechanical Technological College, SME, Speciality chemicals, Tourism

DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The "Knowledge Management - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The "Knowledge Management - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market encompassing Systems, Mechanisms & Technologies, Processes, Infrastructure, Large Enterprises, Small and Medium-sized Enterprises (SMEs), and Knowledge Management exhibits promising growth prospects.
  • Revenue figures are anticipated to experience consistent growth from 2022 to 2030, building upon a stable expansion observed between 2017 and 2022.
  • In 2022, the Knowledge Management market in the United States is estimated at US$194.7 Billion.

Study Shows Foreign Investment Leads to Substantial Increase in ESG Performance of Chinese Firms

Retrieved on: 
Monday, May 15, 2023
Cheung Kong Graduate School of Business, Pressure, Connect, Deregulation, Business, Research, Carbon, Shanghai-Hong Kong Stock Connect, ESG, Edgeworth Professor of Economics, Office of Financial Research, Film industry, Economics, Mechanism, Bloomberg

Their research paper, titled "Financial Deregulation and ESG: Impacts and Mechanisms," discovered that Chinese firms with access to foreign capital through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs, experienced a significant increase in their ESG performance.

Key Points: 
  • Their research paper, titled "Financial Deregulation and ESG: Impacts and Mechanisms," discovered that Chinese firms with access to foreign capital through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs, experienced a significant increase in their ESG performance.
  • After the launch of the Shanghai Connect program in 2014, companies did not see an immediate increase in their ESG ratings relative to unconnected firms.
  • There are two main theories for why firms might respond to foreign investment with improved ESG performance.
  • At the same time, greater foreign investment in a stock tends to lead to increases in ESG ratings.

Study Shows Foreign Investment Leads to Substantial Increase in ESG Performance of Chinese Firms

Retrieved on: 
Monday, May 15, 2023
Cheung Kong Graduate School of Business, Pressure, Connect, Deregulation, Business, Research, Carbon, Shanghai-Hong Kong Stock Connect, ESG, Edgeworth Professor of Economics, Office of Financial Research, Film industry, Economics, Mechanism, Bloomberg

Their research paper, titled "Financial Deregulation and ESG: Impacts and Mechanisms," discovered that Chinese firms with access to foreign capital through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs, experienced a significant increase in their ESG performance.

Key Points: 
  • Their research paper, titled "Financial Deregulation and ESG: Impacts and Mechanisms," discovered that Chinese firms with access to foreign capital through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs, experienced a significant increase in their ESG performance.
  • After the launch of the Shanghai Connect program in 2014, companies did not see an immediate increase in their ESG ratings relative to unconnected firms.
  • There are two main theories for why firms might respond to foreign investment with improved ESG performance.
  • At the same time, greater foreign investment in a stock tends to lead to increases in ESG ratings.

Seismic Therapeutic Announces Presentation of Preclinical Data for Immunoglobin Sculpting Enzyme and Dual-Cell Bidirectional Antibody Programs at IMMUNOLOGY 2023

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Pharmaceutical, Health, Detail, Enzyme, Myasthenia gravis, Inflammation, Multiple sclerosis, Lupus, Doctor of Philosophy, Homeostasis, APC, Journal, Mechanism, Chronic inflammatory demyelinating polyneuropathy, MD, Machine learning, IMPACT, Immunoglobulin G, DCB, AAI, Entrepreneurship, Poster, IG, Standard of care, Rheumatoid arthritis, Vaccine, Seismology, Autoimmunity, Immunology

Enzymes that specifically cleave antibodies may eliminate circulating and immune-complexed Ig, as well as cell surface B cell receptors, thereby modulating Ig-mediated autoimmunity and inflammation.

Key Points: 
  • Enzymes that specifically cleave antibodies may eliminate circulating and immune-complexed Ig, as well as cell surface B cell receptors, thereby modulating Ig-mediated autoimmunity and inflammation.
  • Seismic’s DcB antibody approach targets dysregulated cell-mediated immunity by optimally engaging both T cells and antigen presenting cells (APCs), such as B cells to restore homeostasis.
  • “Our lead Ig sculpting program, a pan-IgG protease, is suitable for the treatment of acute and chronic autoantibody mediated diseases.
  • We are also applying our insights to design additional Ig sculpting enzymes that are selective for IgG subclasses and other Ig isotypes.

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Retrieved on: 
Thursday, April 20, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Partnership, Therapy, Senior, Head, Development, Neoplasm, Cancer, Bristol Myers Squibb, P5, Doctor of Philosophy, BMY, Mechanism, Patient, ADC, BMS, Spacecraft, NYSE, Pharmaceutical industry, Rida al-Tubuly

Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs).

Key Points: 
  • Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs).
  • Through the license agreement, Bristol Myers Squibb will gain exclusive rights to access Tubulis’ Tubutecan payloads in combination with Tubulis’ proprietary P5 conjugation platform for the development of a selected number of highly differentiated ADCs to treat solid tumors.
  • Following antibody target selection by Bristol Myers Squibb, Tubulis will provide the company with its linker-payload to generate a uniquely matched ADC for each antibody.
  • Bristol Myers Squibb will assume sole responsibility for development, manufacturing, and commercialization of the resulting ADC candidates.